Pancreatic and bile duct safety concerns linked to GLP-1 receptor agonists and tirzepatide based on FDA report analysis

The evaluation of adverse event reporting signals for four drugs shows a rising concern about their pancreatic and biliary safety.

• Glucagon-like peptide-1 receptor agonists (GLP-1RAs) include liraglutide, semaglutide, tirzepatide, and dulaglutide.
• The study analyzed data from the US Food and Drug Administration Adverse Event Reporting System (FAERS).
• Concerns regarding pancreatic and biliary safety are associated with the use of these GLP-1RAs.
• Increased reporting of adverse events may indicate a growing awareness or incidence of related safety issues.

Simplified